CytomX Therapeutics (CTMX) Invested Capital (2014 - 2026)

CytomX Therapeutics has reported Invested Capital for 13 years, with the latest figure at $319.9 million in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital rose 1177.27% year-over-year to $319.9 million; the trailing twelve-month figure through Mar 2026 stood at $319.9 million (up 1177.27% YoY), and the FY2025 full-year result was $99.0 million, up 21812.28% from the prior year.
• Invested Capital for Q1 2026 stood at $319.9 million, up from $99.0 million in the prior quarter.
• The five-year high for Invested Capital was $319.9 million in Q1 2026, with the low at -$86.6 million in Q1 2023.
• Historically, Invested Capital has averaged $3.7 million across 5 years, with a median of -$31.2 million in 2024.
• Annual changes were most pronounced in 2022 — Invested Capital tumbled 18582.14% — and 2025, when it jumped 21812.28%.
• CytomX Therapeutics' Invested Capital stood at -$85.8 million in 2022, then jumped by 44.67% to -$47.4 million in 2023, then jumped by 99.04% to -$456000.0 in 2024, then jumped by 21812.28% to $99.0 million in 2025, then jumped by 223.15% to $319.9 million in 2026.
• The last three Invested Capital figures came in at $319.9 million (Q1 2026), $99.0 million (Q4 2025), and $107.4 million (Q3 2025), per Business Quant data.